Last updated on December 2016

A Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute Pain


Brief description of study

Patients with moderate to severe pain caused by medical conditions or surgery, who require IV opioid therapy may be enrolled in this open label safety study. Patients will be treated with TRV130 by IV bolus, PCA (patient-controlled analgesia) administration, or both, as determined by the investigator, for a duration not to exceed 14 days.

Detailed Study Description

The duration of treatment for each patient will be determined by the clinical need for parenteral opioid therapy. Eligible patients with moderate to severe pain caused by medical conditions or surgery, who require IV opioid therapy may be enrolled in this open label safety study. Patients will be treated with TRV130 by IV bolus, PCA administration, or both, as determined by the investigator, for a duration not to exceed 14 days. The duration of treatment for each patient will be determined by the clinical need for parenteral opioid therapy. A follow-up assessment will take place 2-3 days after the completion of the treatment phase.

Clinical Study Identifier: NCT02656875

Contact Investigators or Research Sites near you

Start Over

Trevena Clinical Operations

Recruiting
Mobile, AL United States
  Connect »

Trevena Clinical Operations

Recruiting
Pasadena, CA United States
  Connect »

Trevena Clinical Operations

Recruiting
Miami, FL United States
  Connect »

Trevena Clinical Operations

Recruiting
Shreveport, LA United States
  Connect »

Trevena Clinical Operations

Recruiting
Jackson, MS United States
  Connect »

Trevena Clinical Operations

Recruiting
State College, PA United States
  Connect »

Principal Investigator, MD

Houston, TX United States
  Connect »

Trevena Clinical Operations

Recruiting
Murray, UT United States
  Connect »